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Background: Limited knowledge of stem cell therapies` mechanisms of action hampers their sustainable imple-
mentation into the clinic. Specifically, the interactions of transplanted stem cells with the host vasculature and its
implications for their therapeutic efficacy are not elucidated.We testedwhether adhesion receptors and chemokine
receptors on stem cells can be functionally modulated, and consequently if such modulation may substantially
affect therapeutically relevant stem cell interactions with the host endothelium.
Methods: We investigated the effects of cationic molecule polyethylenimine (PEI) treatment with or without
nanoparticles on the functions of adhesion receptors and chemokine receptors of human bone marrow-
derived Mesenchymal Stem Cells (MSC). Analyses included MSC functions in vitro, as well as homing and
therapeutic efficacy in rodent models of central nervous systems pathologies in vivo.
Findings: PEI treatment did not affect viability, immunomodulation or differentiation potential of MSC, but
increased the CCR4 expression and functionally blocked their adhesion receptors, thus decreasing their adhe-
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2 R. Sch€afer et al. / EBioMedicine 60 (2020) 102987brain was highly increased with decreased numbers of adherent PEI-MSC in the lung vasculature. Moreover,
in comparison to untreated MSC, PEI-MSC featured increased tumour directed migration in a mouse glioblas-
toma model, and superior therapeutic efficacy in a murine model of stroke.
Interpretation: Balanced stem cell adhesion and migration in different parts of the vasculature and tissues
together with the local microenvironment impacts their therapeutic efficacy.
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Stem cell therapies hold great promise for a wide variety of dis-
eases including degenerative diseases and cancer [1]. Although their
therapeutic mechanisms of action (MoA) involve paracrine effects[2], it is under debate if and to which extend (stem) cell therapeutics
require reliable and sufficient delivery to the desired anatomic loca-
tions [3,4].
Systemically administered stem cells are recruited to the site of
injury by responding to attracting factors [4,5]. However, the major-
ity of the transplanted cells accumulate as a first pass effect in paren-
chymal organs such as the liver, spleen and lung [4,5]. The
mechanisms of this phenomenon are not fully understood, but may
involve non-specific trapping of large graft cells in small pulmonary
vessels [4,5] in combination with integrin activation [6,7]. Notably,
undirected stem cell accumulation in various organs and tissues, as
well as vessel obstruction, can increase the risk of side effects. Specifi-
cally, vascular embolism by systemically administered stem cells,
being widely reported in preclinical studies, can depend on cell dose
and infusion velocity of the graft [6,8,9]. Moreover, small vessel
entrapment of systemically delivered stem cells reduces their viabil-
ity, leading to their fragmentation after intravenous (i.v.) infusion [10
−12]. Therefore, it is reasonable to assume that the homing capacity
of the transplanted stem cells is essential for their therapeutic effi-
cacy, and targeting stem cell delivery is required for dose finding and
a prerequisite to unfold their full therapeutic potential.
Due to known interactions between transplanted cells and the
hosts pulmonary epithelium [5,13−16], different strategies have
been developed to optimize stem cell homing. These include increas-
ing the expression of C-X-C chemokine receptor type 4 (CXCR4) [17],
or very late antigen-4 (VLA-4) [18], hematopoietic cell E-/L-selectin
ligand (HCELL) [19], or P-selectin glycoprotein ligand-1 (PSGL-1) [20]
engineering, or a proteolytic modification of the stem cell surface
[21]. However, each of the existing approaches addressed only one or
a few of the many complex processes involved in the stem cellsinter-
actions with the endothelium, and for nearly a decade no significant
progress has been made to clarify the general relevance of such con-
cepts in different disease models of tissue degeneration or cancer.
Addressing this knowledge gap we hypothesized that efficient
stem cell delivery to the site of injury would logically require a func-
tional balance of chemokine receptors and adhesion molecules, as
well as sufficient trans-endothelial migration. Thus, we developed a
novel concept to evaluate the relevance of graft homing as MoA for
stem cell therapies, mechanistically focusing on adhesion and migra-
tion.
Integrins and VCAM-1 play important roles in adhesion and trans-
migration [5], and the CD44-hyaluronan and CXCR4-SDF-1 axes play
pivotal roles in stem cell trafficking [14,22]. Cations dose-depen-
dently regulate integrin and selectin functions [23−25]. PEI features a
high cationic charge density potential, and we hypothesized that it
could interact with receptors that mediate stem cell adhesion to EC,
resulting in targeted stem cell homing to lesioned tissue hallmarked
by high chemokine levels. Therefore, we investigated the applicabil-
ity of cationic agent PEI treatment to modulate adhesion receptor
function. We previously showed that PEI forms complexes with iron
nanoparticles (NP) on MSC surfaces before being incorporated by
endocytosis [26]. Thus, to assess interactions of PEI-NP complexes
with molecules involved in MSC adhesion and migration, we also
tested the combined formulation of PEI with NP.
Hereby, our study highlights the relevance of stem cellshoming
for their therapeutic efficacy.
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2.1. Overview of in vitro and in vivo studies
The concept of the study was to investigate the relevance of adhe-
sion and migration of transplanted MSC for their therapeutic efficacy.
Thus, we treated the MSC with either PEI or with PEI-NP to study the
impact on expression and function of their adhesion and chemokine
receptors in vitro. The results were then further validated in vivo
focusing on the endpoints of first-passage filtering in the lung, tar-
geted homing and migration to lesioned tissue, as well as therapeutic
potential.
In our in vitro and in vivo studies, we investigated human BM-
MSC that were collected from at least 10 individual donors of both
genders. After basic characterization of the MSC, we assessed the
detectability of chemokine and adhesion receptors on their surface
by flow cytometry and the respective mRNA expression of these
genes after treatment with PEI or with PEI-NP. For selected targets
we additionally quantified their intra- and extracellular presence by
ELISA. Receptors that could not be detected were not further ana-
lysed. Additionally, PEI/PEI-NP treatment effects on MSC functions
such as differentiation, immunomodulation and trophic factor pro-
duction were investigated in vitro. Next, we explored the impact of
PEI/PEI-NP-mediated receptor modulation on MSC adhesion and
migration in vitro including specific receptor blocking.
As this allowed us to modulate MSC adhesion and migration in
vitro, we next tested the functional blockade of adhesion receptors
together with increased chemokine receptor expression of MSC in
vivo. Specifically, we addressed the first-pass effect of PEI-treated
and untreated MSC in the lung and targeted homing in a rat quino-
linic acid (QA) brain lesion model and the tissue migration of MSC in
a mouse glioblastoma model. To better understand, whether and to
which extent the migration of exogenously applied stem cells may be
intrinsically predetermined by the organ-specific chemokine milieu
in health and disease, brain and lung chemokines were quantified in
healthy, QA-lesioned and spontaneously hypertensive stroke prone
rats (SHRSP). Finally, we evaluated the therapeutic effects of PEI-
treated and untreated MSC in a murine stroke model.
2.2. Ethics statements
Human BM was obtained after informed consent and its use was
approved by the institutional review boards (ethical committees) of
the Universities of T€ubingen (reference number 76/2009BO2) and
Frankfurt (reference number 329/10).
All animal experiments were carried out in accordance with insti-
tutional animal welfare guidelines and approved by the local institu-
tional committee of Animal Welfare in T€ubingen and Duisburg-Essen.
2.3. Primary cells, cell lines and cell cultures
BMwas taken under sterile conditions from donors after informed
written consent during orthopedic operations: From each donor 5-10
mL of whole BMwas collected in a sterile syringe.
To isolate human MSC from whole BM we used the technology as
described previously [27]. Briefly, BM mononuclear cells were iso-
lated by density gradient centrifugation on Lymphoflot (Biotest,
Dreieich, Germany), washed twice with PBS (Lonza, Walkersville, U.S.
A.), counted and seeded at a density of 1 £ 105 cells per cm2 in
medium composed of a-MEM (Lonza), 1% penicillin-streptomycin
(PS; Lonza) and 10% fetal calf serum (FCS; Lonza, Switzerland) or 10%
human AB serum (ZKT, T€ubingen, Germany) to tissue culture flasks
(Nunc, Roskilde, Denmark). The resulting passage (P) 0 cultures were
kept at 37 °C in humidified atmosphere with 5% CO2. Non-adherent
cells were removed by washing after 24 h and medium was changed
twice a week. Subconfluent MSC were detached using Trypsin-EDTA(Lonza), counted using a CASYࣨ cell counter (Roche, Basel, Switzer-
land) and plated to fresh tissue culture flasks for the next passage
(P1) at a density of 1,000 cells per cm2.
Primary human aortic endothelial cells (hAoEC) and primary
human pulmonary microvascular endothelial cells (hpMEC) were
purchased from Promocell, Heidelberg, Germany. Primary human
brain microvascular endothelial cells (hbMVEC) were purchased
from Pelo Biotech GmbH, Planegg, Germany.
2.4. Transduction of human BM-MSC with green fluorescent protein
(GFP)
Human eGFP+ BM-MSC were generated by the eGFP-encoding bi-
cistronic murine stem cell virus derived retroviral vector (pMIGR1)
system as described previously [28,29] or by the Mission TurboGFPTM
lentiviral particles system (Sigma-Aldrich).
2.5. U87MG-DsRed-Virus production and Transfection of U87MG cells
A lentivirus was engineered from lentiviral backbone plasmid
pPRIME-mating recipient plasmid with CMV promoter controlling
dsRed expression by transfecting HEK 293T cells with a mix of 15 mg
of pPRIME-CMV-dsRed-recipient, 10 mg of packaging plasmid
(pSPAX2) and 6 mg of coat plasmid (pMD2G) [30]. The pPRIME-CMV-
dsRed-recipient was a gift from S. Elledge (Addgene plasmid #
11658) [31]. The virus-containing medium was harvested and pooled
during two days. The virus was then concentrated 10-fold by ultra-
centrifugation (80,000 x g at 4 °C for 90 min) and used for infection.
On the day of infection, medium was removed and 1 mL of virus
10x supplemented with protamine sulphate (8 mg/mL) was applied
to the U87MG cells drop by drop. After 3 days, the medium was
exchanged with fresh culture medium to amplify the cells. A flow
cytometry with fluorescence activated cell sorting (FACS) was per-
formed to separate the DsRed positive cells from the non-infected
cells based on fluorescent labelling. The sorted DsRed-positive
U87MG cells were re-plated and amplified until usage.
2.6. Treatment of human BM-MSC with polyethylenimine alone or in
combination with iron nanoparticles
Human BM-MSC treatment was performed at 90% confluency for
4 h in T-75 flasks. One day before treatment, cell culture media were
changed and reduced to 9 mL per flask. The next day, MSC were
treated for 4 h with the cationic linear polyethylenimine jetPEITM
(PolyPlus Transfection, Illkirch, France) at a final concentration of
10mL/mL (PEI-MSC), or with a formulation of 10mL/mL jetPEITM plus
60 mg/mL Ferucarbotran (Resovist, Bayer Schering AG, Berlin, Ger-
many) consisting of superparamagnetic iron oxide nanoparticles
(mean particle diameter 4−6 nm) coated with carboxydextran (mean
hydrodynamic diameter 60 nm) as described previously (PEI-NP-
MSC) [26]. During the treatment the cells were kept in the incubator
(37 °C, 5% humidified CO2). After the treatment the cells were washed
with PBS and cultivated for 24 h in 15 mL culture medium before the
harvest and processing for in vitro assays or in vivo transplantation.
2.7. In vitro MSC differentiation assays
MSC can be functionally characterised by their in vitro differentia-
tion capacity, and we evaluated the differentiation potential into the
adipogenic, osteogenic and chondrogenic lineage as described previ-
ously [27]. Briefly, for adipogenic and osteogenic differentiation MSC
were seeded at a density of 1000 cells per cm2 and kept under stan-
dard culture conditions until reaching subconfluency. Subsequently,
either adipogenic differentiation was induced using the hMSC Adipo-
genic BulletKit (Lonza), or osteogenic differentiation was induced
using “osteogenic medium” composed of a-MEM (Lonza), 1% PS
Table 1





CD29 FITC IgG1 Serotec
CD44 FITC IgG1 R&D
CD49a PE IgG1 BD Biosciences
CD49d PE IgG1 R&D
CD49e PE IgG1 R&D
CD62P FITC IgG1 R&D
CD105 FITC IgG1 R&D
CD106 FITC IgG2a R&D
CCR1 FITC IgG2b R&D
CCR4 PE IgG2b R&D
CCR5 PE IgG2b R&D
CCR6 PE IgG2b R&D
CCR7 FITC IgG2a R&D
CCR9 PE IgG2a R&D
CXCR4 FITC IgG2a R&D
CXCR5 PE IgG2b R&D
CXCR6 PE IgG2b R&D
4 R. Sch€afer et al. / EBioMedicine 60 (2020) 102987(Lonza), 10% FCS, 108 M dexamethasone, 0.2 mM ascorbic acid and
10 mM b-glycerolphosphate (Sigma-Aldrich). After three weeks
under differentiation conditions, lipid vacuoles in adipogenic cultures
were stained with Oil Red O and calcium deposits of osteogenic cul-
tures with Alizarin Red S, respectively. For chondrogenic differentia-
tion, 2.5 £ 105 MSC were kept in micromass pellet cultures.
Differentiation was induced using the hMSC Chondrogenic Differenti-
ation BulletKit (Lonza), supplemented with TGF-b 3 (Lonza) as a
growth factor. After four weeks of differentiation, frozen sections of
fixed pellets were performed and stained with Alcian blue.
2.8. Flow cytometry analyses
To assess the characteristic surface epitope pattern of human BM-
MSC, flow cytometry analysis of surface marker expression was per-
formed with a FACScan (BD Biosciences, Heidelberg, Germany) using
BD CellQuest ProTM software and the following antibodies: anti-
CD10, -CD14, -CD15,-CD19, -CD29, -CD31, -CD34, -CD43, -CD44,
-CD45, -CD56, -CD59, -CD71, -CD73, -CD90, -CD105, -CD106, -CD117,
-CD130, -CD140a, -CD140b, -CD146, -CD166, -GD2, -HLA class I and
-HLA class II (BD Biosciences); -CD93 (R&D Systems, Minneapolis, U.
S.A.); -CD133 and -CD271 (Miltenyi Biotec, Bergisch-Gladbach, Ger-
many); -CD243 (Millipore); -CD173 (AbD Serotec, Puchheim, Ger-
many) and -W8B2 (BioLegend, San Diego, U.S.A.). Podoplanin (PDPN)
expression was analysed with rat anti-human-podoplanin antibody
(BioLegend). PE-conjugated or non-labeled IgG1, -IgG2a and -IgM
antibodies (BD Biosciences) were used as isotype matched controls.
Secondary antibody was a polyclonal PE-conjugated goat anti-mouse
Ig (BD Biosciences).
Flow cytometry analysis for the evaluation of the homing recep-
tors on the cellular surface of MSCs was performed with FACSort flow
cytometer (BD Biosciences) using BD CellQuest ProTM software. The
cells were detached with AccutaseTM (GE Healthcare) 24 h after treat-
ment, washed and re-suspended in FACS buffer (PBS + 0.1% FCS).
Each sample contained a cell suspension with 2 £ 105 cells in 100 mL
FACS buffer. Staining was performed according to the manufacturer`s
instructions with FITC- or PE-conjugated antibody and incubated for
30 min in the dark, followed by two washing steps. The following
antibodies were used to investigate the expression of cell adhesion
receptors and chemokine receptors on untreated MSC: Anti-human-
a-1integrin (CD49a/VLA-1), -a-4integrin (CD49d/VLA-4),
-b-1integrin (CD29), -H-CAM (CD44), -P-Selectin/LECAM-3 (CD62P),
-endoglin (CD105), -VCAM (CD106), -CCR1 (CD191), -CCR4 (CD194),
-CCR5 (CD195), -CCR6 (CD196), -CCR7 (CD197), -CXCR4 (CD184),
-CXCR5 (CD185), -CXCR6 (CDw186/BONZO), and -CCR9 (CDw199).
The following antigens that were found to be expressed on untreated
MSC were used to further analyse MSC treated with PEI alone or in
combination with nanoparticles: Anti-human-a-1integrin (CD49a/
VLA-1), -a-4integrin (CD49d/VLA-4), -b-1integrin (CD29/VLA-4), -H-
CAM (CD44), -P-Selectin/LECAM-3 (CD62P), -endoglin (CD105),
-VCAM (CD106), -CCR4 (CD194), -CXCR4 (CD184), and -CCR9
(CDw199). For details of fluorescence conjugation, immunoglobulin
subtype/isotype and vendors see Table 1 below. For analysis, the geo-
metric mean of the fluorescence intensity was used. To compare to
antigen expression on treated and untreated MSC, the antigen
expression on untreated MSC was set at 100%. Data were analysed as
relative values according to the respective untreated MSCs of the
same MSC preparation (donor). To analyse PEI dose-dependent CCR4
expression human BM-MSC were treated with different PEI doses
(1.0%, 0.5% and 0.25%), and CCR4 staining was performed as described
above.
2.9. Determination of cell viability and diameter
Cellular viability and diameter of detached cells was examined
with the CASY2 Cell Counter and Analyzer System, Model TT (RocheDiagnostics, Mannheim, Germany) according to the ECE method
described by Lindl et al. [32].2.10. In vitro migration assays
Human BM-MSC in vitro migration capacities were analysed using
a 6-well transwell chamber system (Polyethylene Terephthalate
membrane; pore size: 8mm [Corning, Treyburn, NC, U.S.A]).
Migration medium (a-MEM + 10% human platelet lysate
[HPL] + 1%PS + 2IU heparin/mL) without or with cytokines (25 ng/mL
PDGF-BB, or 200 ng/mL CCL2 all from Peprotech, Rocky Hill, NJ, U.S.
A.) was added to the lower compartment. Then untreated or PEI-
treated human BM-MSC (2.8 £ 105 cells per well) in migration
medium without cytokines were placed into the upper compart-
ments. After 24 h migration time cells and medium from the upper
compartments were discarded. To harvest all transmigrated cells the
medium of the lower compartments was collected and possibly
adherent cells were detached from the lower side of the membrane
and the surface of the well by incubation with AccutaseTM (Gibco) at
+37 °C. After 5 min the enzyme activity was antagonized with com-
plete medium and the lower side of the membrane and the well were
rinsed thoroughly, and the detached cellssuspension was added to
the migration medium from the lower compartment. Subsequently,
transmigrated hBM-MSC were lysed and quantified by CellToxTM
Green Cytotoxicity Assay (Promega, Madison, WI, USA).
To investigate the migration capacity of human BM-MSC subpo-
pulations the above described 6-well transwell chamber system was
used. First, migration medium (a-MEM + 20% pooled human serum
[IKET, T€ubingen, Germany] + 1%PS) without or with cytokines (50 ng/
mL CCL2 or 20 ng/mL CXCL12, both from Peprotech) was added to
the lower compartment. Then untreated or PEI-treated pooled (6
donors) human BM-MSC (2.8 £ 105 cells per well) in migration
medium without cytokines were placed into the upper compart-
ments. Additionally, untreated or PEI-treated pooled (6 donors)
human BM-MSC were seeded in 6 well plates without transwell
inserts as reference group. After 24 h the cells were harvested as
described above and analysed, using 7AAD dead cell exclusion stain-
ing, by flow cytometry. Human BM-MSC subpopulations were identi-
fied by labelling with anti-CD10 (BD Biosciences), anti-CD140b (BD
Biosciences), anti-CCR4 (R&D), or anti-GD2 (BD Biosciences). Migra-
tion capacities of human BM-MSC subpopulations were assessed by
analyses of percent of migrated antigen positive cells normalized to
percent antigen positive cells of the respective reference groups.
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Supernatants of treated or untreated human BM-MSC were col-
lected and subjected to differential centrifugation (all steps at 4 °C):
10 min at 130 x g to clear supernatants from cell debris, followed by
30 min at 10,000 x g to pellet microvesicles (MVs), and ultracentrifu-
gation for 2 h at 100,000 x g to pellet small EV. The final 100,000 x g
pellet was re-suspended in PBS and analysed using the Nanosight
LM10 system at 23 °C (green laser 532 nm, syringe pump, Nanosight
2.3 software). The following settings were used: Camera level =16,
particle detection with a screen gain of 16, a detection threshold of 7
and the setting “minimum expected particle size auto”. A script con-
trol was used (repeat start, syringe load 500, delay 5, syringe stop,
delay 15, capture 30, repeat 4). Per sample five 30 s videos were
recorded, the particles were tracked and average values were calcu-
lated to express particle number over size.
2.12. Immunocytochemistry and immunohistochemistry
For the immunofluorescence staining of CXCR4 in vitro, human
BM-MSC were cultured and treated with PEI or PEI-NP in chamber
slides (Becton Dickinson). Cell samples were incubated with the pri-
mary antibody against CXCR4 or an isotype control (both IgG2B,
R&D), 1:25, followed by incubation with the secondary fluoro-
chrome-labelled antibody (Alexa Fluor 488, Invitrogen) 1:300, for
30 min at 37 °C each. Samples were embedded in mounting medium
containing DAPI and documented with a fluorescence microscope
(Zeiss) and the AxioVision Rel. 4.8 software (Zeiss).
Brain and lung sections of QA-lesioned rats, selected from the
vicinity of the sections containing human eGFP+BM-MSC, were fixed
with methanol at 20 °C, washed and subsequently incubated with
antibodies against von Willebrand factor (vWF) diluted 1:300 (rabbit
polyclonal, DakoCytomation, Glostrup, Denmark), or SDF-1 diluted
1:50 (rabbit polyclonal, Abcam), or CCL2 diluted 1:200 (rabbit poly-
clonal, Biozol, Eching, Germany) for 2 h at room temperature (RT).
Brain sections were also stained with CXCR4 antibodies, diluted
1:300 (R&D) for 2 h at RT. Sections were washed with PBS and further
incubated with Cy3-conjugated goat anti-rabbit IgG diluted 1:500
(Dianova, Hamburg, Germany) for 1 h at RT. Thereafter, samples
were washed with 0.05% Triton (Sigma-Aldrich) in PBS, coated with
Vectashield mounting medium containing DAPI and assessed by fluo-
rescence microscopy.
Immunohistochemical analyses of brain sections from mice with
focal cerebral ischemia were performed as described before [33].
Briefly, 16-mm thick coronal cryostat sections were obtained after
sacrifice of animals and subsequent transcardial perfusion with both
PBS and 4% paraformaldehyde. Quantitative analysis was performed
in four regions of interest (ROI) within the ischemic basal ganglia, i.e.,
at 0.14 mm anterior, 2.5−3.25 mm ventral, and 1.5−2.25 mm lateral
from bregma. Three sections per animal and ROI were used.
Brain sections were stained with polyclonal rabbit anti-GFP anti-
body (1:2,500; Abcam, U.K.), goat anti-doublecortin antibody (1:50;
Santa Cruz Biotechnology), polyclonal rat anti-GFAP antibody (1:500;
Zymed, Germany), monoclonal mouse anti-CNPase antibody (1:400;
Millipore, U.K.), monoclonal mouse anti-NeuN antibody (1:1,000;
Millipore) and monoclonal mouse anti-nestin antibody (1:500; Milli-
pore). Sections were then incubated with goat anti-mouse Cy-3
(1:100; Jackson ImmunoResearch, U.K.), goat anti-rat Cy-3 antibody
(1:200, Abcam), and donkey anti-goat Cy-3 secondary antibody
(1:500; Dianova) respectively.
2.13. Immune cell proliferation assays
The immunosuppressive properties of PEI/NP treated and
untreated human BM-MSC were analysed in co-culture assays with
activated allogeneic immune cells. Four PEI/NP treated and untreatedhuman BM-MSC preparations were mitotically inactivated by treat-
ment with 40 mg/mL mitomycin c for 30 min at 37 °C in serum free
medium. Thereafter, the MSC were washed three times, counted and
seeded to 96-well plates in triplicates at a density of 2 £ 104 cells per
well. After 24 h, 1 £ 105 peripheral blood mononuclear cells
(PBMNC), freshly isolated by density-gradient centrifugation from
heparinized blood of 2 unrelated healthy donors, were added to the
respective wells of BM-MSC cultures. Immune cells were stimulated
with 10 mg/mL phytohaemagglutinin-L (Sigma-Aldrich) and cultured
for 72 h under standard culture conditions. During the last six hours,
100 mM bromodeoxyuridine (BrdU) labelling solution from the Cell
Proliferation ELISA, BrdU (colorimetric) Kit (Roche) was added to the
(co-) cultures and cell proliferation was assessed by ELISA, using the
anti-BrdU antibody provided in the kit according to the manufac-
turer’s instructions. Photometric light absorption was measured in a
plate reader and absorbance values were averaged and normalized to
the PBMNC only control of the respective blood donor.
2.14. RNA isolation and qRT-PCR analyses
RNA from PEI-MSC, PEI-NP-MSC, as well as from untreated MSC
from 10 unrelated donors was isolated using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions. Remaining genomic DNA was digested using the RNase-Free
DNase Set (Qiagen). RNA concentration was assessed using a Nano-
Drop photometer (ThermoFisher Scientific). RNA was stored at 80 °
C for up to three months. For analysis by quantitative PCR, 0.5 mg
RNA (samples for CXCR4 mRNA and H-CAM mRNA) or 1 mg RNA
(samples for endoglin mRNA, VCAM-1 mRNA, integrin a 1 mRNA, and
CCR4 mRNA) from each sample was reverse transcribed using the
Transcriptor First Strand cDNA Synthesis Kit (Roche) or the Tetro
cDNA Synthesis Kit (Bioline, Luckenwalde, Germany) according to
the manufacturer’s instructions. Resulting cDNA was stored at -20 °C
for up to 6 months. For expression analysis of CXCR4 mRNA, H-CAM
mRNA, endoglin mRNA, VCAM-1 mRNA, integrin a 1 mRNA, CCR4
mRNA and GAPDH mRNA as housekeeping gene, PCR analysis of
cDNA was performed using ready-to-use amplification primer mixes
for RT-PCR (search-LC, Heidelberg, Germany) in combination with
LightCycler FastStart DNA Master SYBR Green I (Roche) and the Light-
Cycler Instrument (Roche), according to the manufacturer’s instruc-
tions. PCR results were analysed by normalizing the expression of
each target gene to the expression of the housekeeping gene GAPDH
in each sample.
2.15. Protein isolation and Western blot analyses
Western blotting was performed using protein lysates from PEI/
NP-treated or untreated human MSC and from brain homogenates of
unilaterally QA-lesioned rats. The total protein was determined by
DC Protein assay (Bio-Rad). For each lane, 50 mg of protein were sub-
jected to sodium dodecyl sulphate polyacrylamide gel electrophore-
sis in a 12.5% or 10% gel and transferred to PVDF membranes by tank
blotting. Membranes were blocked in 0.66% (v/w) I-Block or 5% w/v
nonfat dry milk (Tropix, Applied Biosystems, Weiterstadt, Germany)
in PBST or TBST (0.05% Tween 20 in PBS or TBS, with pH 7.4) for 1.5 h.
Antibodies against CXCR4 (1:500, AbD Serotec), CD44 (1:1000, Cell
Signaling Technology, Danvers MA, USA), CCL-2 (1:500, Biozol), and
GAPDH (1:1000, loading control, Millipore) were used.
2.16. ELISA, Luminex and V-plex assays
In order to investigate whether the treatment of MSC with PEI
+/-NP could split off the soluble fraction from the CD44 molecule
hereby altering the function of CD44, we quantified CD44 protein in
the supernatants of untreated and treated human BM-MSC by Human
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turer (Bender MedSystems, Vienna, Austria).
The capacity to produce and secrete trophic factors that have been
shown to mediate therapeutic effects of MSC was assessed in super-
natants and lysates of untreated and treated human BM-MSC. Pooled
human BM-MSC (8 donors) were seeded at P2 into 12-well plates in
biological triplicates at a density of 20,000 cells/cm2. After 24 h, cells
were treated with PEI or PEI+NP, or kept in standard culture medium
as untreated control. During the treatment the cells were kept in the
incubator (37 °C, 5% humidified CO2 atmosphere). Thereafter, treated
and untreated cells were washed with PBS and cultivated under stan-
dard culture conditions for another 24 h. Culture supernatants were
transferred to Eppendorf vials and frozen at 80 °C for following
analysis. Cell monolayers were washed with ice cold PBS, lysed in
400mL Procarta lysis buffer (Affymetrix) and frozen at 80 °C. Sam-
ples were sent to Multimetrix (Heidelberg, Germany) for multiplex
analysis of expression of HGF, LIF, VEGF-A, FGFb and NGF-b in a com-
mercial Luminex system. For analysis of BMP4 and angiopoietin-1
expression, samples were analysed using Quantikine ELISA systems
(R&D) according to the manufacturer’s instructions. All samples were
analysed in technical duplicates.
For analyses of cytokines, the brains and lungs of QA-lesioned,
SHRSP and normal Sprague-Dawley rats (Charles River) were proc-
essed in ice-cold lysis buffer (300 mmol/L NaCl, 50 mmol/L Tris,
2 mmol/L MgCl2, 0,5% NonidetTM P40, containing a Complete Protease
Inhibitor Tablet from Roche Diagnostics at a ratio of 1:5 (tissue
weight/buffer volume). The tissue was disrupted using a Micro Dis-
membrator II (B.Braun, Melsungen, Germany) at maximal amplitude
for 30 s in a Teflon container which had been precooled with liquid
nitrogen. Thereafter, homogenates were clarified by centrifugation at
20,000 x g and 4 °C for 15 min. Determination of rat cytokines (mono-
cyte chemotactic protein [MCP]-1, interferon [IFN]-g , tumor necrosis
factor [TNF]-a, regulated and normal T cell expressed and secreted
[RANTES], interleukin [IL]-1a,IL-1b, IL-6, IFN-g-induced protein [IP]-
10 [CXCL10], MCP-3, and macrophage inflammatory protein [MIP]-
1a) was performed using a multiplex bead immunoassay system
(Procarta Cytokine Assay Kit; Affymetrix, Inc., Santa Clara, CA, U.S.
A.) according to the manufacturer's manual. The results are presented
as pg/mL or pg/mg protein.
For quantification of pro-migratory cytokines primary endothelial
cells derived from human brain (hbMVEC) and from human lung
(hpMEC) were treated with lysis buffer (300 mM NaCl, 50 nM Tris,
2 mM MgCl2, 0.05% NP40) and, after centrifugation (20,000 x g and
4 °C for 15 min), supernatants were harvested.
Total protein concentrations in the supernatants were quantified
with BCA protein assay (ThermoFisher Scientific). Determination of
the human pro-migratory cytokines CCL2, PDGF-BB and TGF-b was
performed using respective ELISA kits (CCL2 and PDGF-BB: Cloud
Clone [Katy, Tx, USA]; TGF-b: Biorbyt [Cambridge, UK]) according to
the manufacturer's manual. The results are presented as pg/mg total
protein.
2.17. Flow chamber assays
HAoEC (Promocell) were seeded into ibidi microslides (m-Slide I
(0.4) Luer, Collagen IV, IBIDI, Munich) at a density of 7.2 £ 105 cells/
cm2 and incubated overnight, resulting in a confluent adherent layer.
HAoECs were then activated with 2.5 ng/mL TNFa (R&D, Wiesbaden,
Germany) for 16 h at 37 °C.
Treated or untreated human BM-MSC from 2 to 5 unrelated
donors (P4 or P5) were washed, detached with trypsin, counted and
adjusted at a concentration of 3 £ 105 cells/mL. The microslides were
incorporated into a flow-based adhesion assay. Briefly, a syringe
pump (PHD 2000, Harvard Apparatus, Natick, MA, U.S.A.) moved the
cell suspension in medium through the microslides at a controlled
rate of 0.1 mL/min, while allowing visualisation of the cells inside theslide by phase contrast microscopy (Axiovert, Zeiss, Oberkochen, Ger-
many). MSC were perfused through the microslides for 10 min. For
analysis of MSC adhesion under shear stress conditions, video
sequences (10 s) were recorded by a digital camera (CF15 MC, Kappa,
Gleichen, Germany). A cell moving less than one cell diameter within
10 s. was defined to be adherent. To measure velocities, images from
these video sequences were digitalized at 25 frames/s, and the dis-
tance of movement of the MSC during the 10 s. interval was com-
puted into pixels. All measurements were performed using
customized software for image recognition as described previously
(CellTracker, C. Zanke, University Hospital T€ubingen, Germany) [34].
To evaluate the influence of surface antigens on adhesion, we con-
ducted blocking experiments with appropriate antibodies. PEI/NP
and untreated human BM-MSC were incubated with 10 mg/mL anti-
CD44 antibodies (BD, Heidelberg, Germany) or anti-CXCR4 antibodies
(R&D Systems) for 30 min. Chinese Hamster Ovary Cells (CHO-A5)
were used as negative controls.2.18. Dynamic adhesion capacity of human BM-MSC in vitro
To analyse PEI treatment effects on adhesion over time, human
BM-MSC were treated with PEI or mock-treated as described. Then
1 £ 104 cells were seeded per well of an 8-chamber slide (Nunc) in
culture medium, 10% FCS. Adhesion was monitored using kinetic live
cell imaging (IncuCyte Zoom, Essen Biotech) in 2-min intervals for
30 min. Phase object area and % confluence were calculated. Integrin
signalling was monitored in parallel chamber slides assessing phos-
phorylation of focal adhesion kinase (FAK) and paxillin (PAX) as
described before [35]. The following antibodies were used: pFAK:
mouse monoclonal IgG1, clone 2D11, 1:50, Santa Cruz; FAK: rabbit
polyclonal IgG, clone C-20, 1:50 (Santa Cruz); pPax: mouse monoclo-
nal IgG1, clone 2D11, 1:50,Santa Cruz; Pax: mouse monoclonal IgG1,
clone 2D11, 1:50 (Santa Cruz).2.19. Quartz Crystal Microbalance with Dissipation (QCM-D)
experiments
All QCM-D experiments were performed using a qCell T instru-
ment (3T analytik, Tuttlingen, Germany) and 10 MHz gold coated
quartz sensor chips at a temperature of 37.2 °C. Before each measure-
ment, the QCM-D setup (i.e., tubes, junctions, crystals and flow cham-
ber) was cleaned with 1% sodium hypochlorite at a flow rate of
100 mL/min for 30 min, and rinsed with Ampuwa (Fresenius Kabi,
Germany) at a flow rate of 800 mL/min for 22 min and culture media
(HEPES-buffered alpha-MEM consisting of 379.05 mL Ampuwa,
50 mL MEM (10x), 12.5 mL HEPES (1M), 3.45 mL Glutamine
(200 mmol), 50 mL human AB serum, 5 mL PS) at a flow rate of
60 mL/min for 3 min, followed by a flow rate of 800 mL/min for
1 min. Cells, with or without PEI/NP treatment or heat treatment
(negative control; 10 min. 57 °C; dead cells), suspended in culture
media at a concentration of 1.3 million cells/mL (corresponding to
about 40,000 cells in the flow chamber with a volume of 30 mL),
were then seeded at stagnant conditions throughout the 4 h meas-
urements. After each measurement, the cells were crystal violet
stained (according to manufacturer’s instructions) and viewed by
microscopy (Axioskop 2MAT, Zeiss). Each condition was carried out
in triplicate.2.20. Animal models and SC transplantations
For all in vivo transplantation experiments human eGFP+ BM-MSC
were used.
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implantation
Stereotactic brain injection of human glioblastoma U87MG-DsRed
cells (1 £ 105 cells in 2 mL of sterile PBS) was performed in 9-weeks
old female NMRI mice (Charles River Laboratories). 22 days after
tumor inoculation 1 £ 105 eGFP+ PEI-treated and eGFP+ untreated
human MSC (N = 4 per group) or PBS (N = 3) were injected contralat-
erally to the following coordinates relative to bregma: DV 3.0; AP
+1.0; ML 1.5. Both glioblastoma and MSC were injected in a total
injection volume of 2mL with a 26 gauge needle (Hamilton, Bonaduz,
Switzerland) at a flow rate of 1 mL/min. Anesthesia was performed
using a mixture of medetomidine (0.5 mg/kg), midazolam
(5.0 mg/kg) and fentanyl (0.05 mg/kg) and was abrogated with
flumazenil (0.5 mg/kg) and atipamezole (2.5 mg/kg). Six days
after injection of PEI-treated and untreated human MSC animals
were euthanised with CO2.
2.22. MR imaging
MR scans were acquired using a 7T ClinScan MR-Scanner (Bruker,
Ettlingen, Germany) eighteen days after implantation of glioblastoma
U87MG-DsRed cells. Animals were anesthetized with a mixture of
1.5% isoflurane (Abbott, Wiesbaden, Germany) evaporated in oxygen
at a flow of 0.5 L/min . A dedicated brain coil was used to obtain
T2-weighted images of the brain. For the maintenance of the body
temperature at 37 °C a heating system connected to a rectal tem-
perature sensor was employed. Image analysis was performed by
Inveon Research Workplace 3.1 (Siemens Preclinical Solutions, Erlan-
gen, Germany)
2.23. Excitotoxic quinolinic acid brain injury and human BM-MSC
transplantation
Male Sprague-Dawley rats (Charles River, weight at start of
experiments: 220−300 g, age 9−11 weeks) were held under constant
climatic conditions in an animal holding room with 12:12 h light-
dark cycle. All experiments were performed in the light phase. The
rats had access to 15 g standard rat chow per day and water ad libi-
tum.
For unilateral lesion of the hippocampus, the animals were anaes-
thetized either with pentobarbital (64 mg/kg) or isoflurane (1−2%) in
air with perioperative fentanyl anaesthesia (3−5mg/kg s.c.). Post-sur-
gery analgesia treatment was performed by carprofen injections
(daily 50 mg/kg s.c.). The head of each animal was fixed in a stereo-
tactic frame (Stoelting, Dublin, Ireland), the skin above the skull was
treated with iodine solution for disinfection, and a short incision was
made through the skin. Small holes were drilled at the distinct ste-
reotactic localization for the hippocampus without injury of the dura
mater. The quinolinic acid (QA, Sigma-Aldrich) microinjection
(60 mmol/mL) was performed by means of a Hamilton microsyringe
(cannula diameter 0.45 mm) over one minute into the left hippocam-
pus (coordinates relative to bregma: AP −3.8 mm, L +2.4 mm, V
−3.2 mm). The cannula was left in place for another two minutes and
was slowly retracted afterwards. The skull holes were carefully
closed by means of bone wax and the skin was closed using 2−4
sutures. In all rats the wound healed without complication within 2
−3 days after surgery.
Untreated, PEI or PEI-NP treated human eGFP+ MSC (5 £ 106 cells)
were re-suspended in 800 ml sterile phosphate buffered saline and
were administered 7 days after surgery by intravenous injection into
the lateral tail vein under a short ketamine-anaesthesia (100−125
mg/kg i.p.). The numbers of animals per group were: 5 (untreated
MSC; immunohistochemistry), 5 (PEI-MSC; immunohistochemistry);
6 (PEI-NP-MSC; immunohistochemistry); 12 (no cells; 6 with lesion,
6 without lesion; multiplex).The preparation of the tissue was performed 24 h after cell admin-
istration after decapitation of the respective animal using a guillotine
under ketamine anaesthesia. Left and right lung and both brain hemi-
spheres were removed and frozen for immunohistochemical and
multiplex analyses as described above.
Sagittal cryosections (20 mm in thickness) were prepared from
the left and right brain hemispheres of rats. For detection of the
human eGFP+ MSC, the sections were stained with 40,6 diamidino-2-
phenylindole (DAPI) (Vector Laboratories Burlingame, CA, USA). For
MSC quantification, sagittal sections were taken at regular intervals
starting from inter-hemispheric fissure and analysed by fluorescence
microscopy using an Olympus BX51 microscope (Olympus) and the
“AnalySIS” software (Soft Imaging System GmbH, Germany). The
numbers of eGFP+ MSC were obtained from the areas of interest (hip-
pocampus, lateral ventricle, striatum) and in total per brain section.
The data shown in Fig. 5 show the number of cells per mm2 quanti-
fied from 50 sections per brain.
Longitudinal cryosections (25 mm in thickness) of the whole left
lung were taken at regular intervals and either mounted with DAPI
for MSC quantification or processed for immunocytochemistry as
described above. MSC quantification was performed from 5 fields per
lung section (30 sections per organ).
2.24. Spontaneously hypertensive stroke prone rats
Male 7 weeks-old spontaneously hypertensive stroke prone
(SHRSP) rats purchased from Charles River were kept in groups of 3
or 4 animals under standardized conditions (air humidity: 60%;
Temp: 22 °C; darkness from 7 pm to 7 am) and given salt-rich (2%)
chow (Altromin, Lage, Germany) and 1% NaCl drinking water solution
ad libitum.
After 12 weeks of salt loaded diet, animals were sacrificed under
ketamine anaesthesia (100 mg/kg, i.p.; Delta Select, Pfullingen, Ger-
many). The brains and lungs were isolated and stored at −80 °C for
further analyses by immunohistochemistry, Western blots and Lumi-
nex assay as described above.
2.25. Induction of focal cerebral ischemia and transplantation of human
BM-MSC
All mice had free access to food and water, and all experiments
were blinded to experimenters. Adult male C57BL6 mice (Harlan,
Germany; 10 weeks old, 25 g) were exposed to 45 min. of transient
focal cerebral ischemia using the thread occlusion model as previ-
ously described [36,37]. Briefly, mice were anesthetized using a vola-
tile mixture consisting of isoflurane (1.5%), nitrogen (78.5%) and
oxygen (30%). Under constant Laser Doppler control of regional blood
flow, a silicon-coated filament (180 mm in diameter; Doccol, USA)
was inserted into the left common carotid artery and gently pushed
upwards into the left middle cerebral artery (MCA). The filament was
withdrawn after 45 min. and regional blood flow was controlled for
an additional 10 min. to ensure proper reperfusion. Subsequently,
1 £ 106 MSC or PEI-MSC were administered into the femoral vein.
Cells were re-suspended in 200 mL PBS and control animals received
200mL PBS only, N = 7 animals per group.
2.26. Behavioural tests
2.26.1. Rotarod, tight rope, corner turn test
For assessment of functional impairment, three well established
behavioural tests were used on days 10, 20 and 28 post-stroke [36].
Before performance of actual tests at the aforementioned days, mice
were trained 1−2 days before stroke induction in order to ensure
proper test performance of animals. The rotarod test was performed
using a treadmill with a diameter of 3 cm (TSE Systems, Germany).
The test was performed using accelerating velocity (4−40 rpm),
Fig. 1. Human MSC adhesion receptor and chemokine receptor analyses after PEI treatment and functional adhesion capacity assessment in vitro
(a) Expression levels of H-CAM (CD44), Endoglin (CD105), VCAM-1, VLA-1, VLA-4 (CD49d, b-1 integrin), P-selectin, CCR4, CCR9, and CXCR4 detected by flow cytometry in
untreated human BM-MSC, and MSC treated with PEI alone or PEI-NP. N = 3−4, each data point represents one biological replicate per group; Flow cytometry data of untreated and
PEI/NP treated MSC were compared with ANOVA followed by Tukey's multiple comparisons test (*p < 0.05; **p < 0.01). Error bars: SD.
(b) Western blot for CD44 and CXCR4 total protein in untreated MSC or treated with PEI alone or in combination with NP. Representative photograph of N = 6 biological
replicates.
(c) Levels of indicated mRNAs measured by qPCR in untreated MSC or treated with PEI or PEI- NP (N = 6−10, each data point represents one biological replicate per group; repli-
cates collectively analysed for the respective targets). mRNA expression data of untreated and PEI/NP treated MSC were compared with ANOVA followed by Tukey's multiple com-
parisons test (*p < 0.05; **p < 0.01; ***p < 0.001). Error bars: SD.
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the time when the animal fell off the treadmill was used for statistical
analysis. Further testing was done using the tight rope, for which
mice were placed with their forepaws at the middle of a 60 cm long
rope that was attached to two opposing platforms. Using a validated
score between 0 (min) and 20 (max) the two parameters “platform
arrival” and “time needed to reach the platform” were assessed. The
test was performed twice per time point and means were calculated.
For the corner turn test, two vertical boards forming an angle of 30°
were used. Mice were placed into the test apparatus and the side cho-
sen to leave the corner after contact with their vibrissae was ana-
lysed. Ten trials per test day were performed. Healthy unaffected
mice randomly leave the corner, whereas mice suffering from cere-
bral ischemia leave the corner from the non-impaired (e.g., left) body
side. The laterality index was calculated as (number of left turns −
number of right turns) / 10.
2.27. Statistical analyses
All data are given as means § standard deviation (SD) or standard
error of means (SEM). Shapiro−Wilk test was applied to test normal
distribution. For multiple comparisons of data obtained in vitro andin vivo (Fig. 1a,c; Fig. 2c,d; Fig. 3c; Fig. 4a,d; Suppl.Fig. 2a,b,e,f,g), one-
way analysis of variance (ANOVA) followed by Tukey’s post-hoc test
was used. For single comparison in the other data sets the two-tailed
t-test was employed. P values of <0.05 were considered to be statisti-
cally significant and are such listed in the Figure legends. For compar-
isons with low sample sizes (N≤4) descriptive statistics are listed in
Supplementary Table 2.
3. Results
Functional blocking cell adhesion receptors and increasing CXCR4
expression modifies MSC adhesion to endothelial cells in vitro
First, we assessed homing and chemokine receptor expression on
MSC in vitro. Untreated MSC did not express CCR1, CCR5, CCR6, CCR7,
CXCR5, and CXCR6 (data not shown), and therefore, these receptors
were not further analysed. PEI treatment of MSC impaired expression
of CD44 (H-CAM), endoglin, CD106 (VCAM-1), and VLA-1 (integrin
a1), but increased CCR4 expression dose-dependently. VLA-1 expres-
sion was also impaired upon PEI-NP treatment of MSC, but in contrast
to PEI treatment, expression of VCAM-1 and CXCR4 were increased.
Treatment of MSC with either PEI or PEI-NP did not affect the expres-
sion of P-selectin, VLA-4 (CD29, integrin b1), or CCR9 (Fig. 1a).
Fig. 2. Functional in vitro adhesion capacity of human MSC after PEI treatment
(a) In vitro integrin signalling analysis by immunocytochemistry of phosphorylated (green) and non-phosphorylated (red) focal adhesion point markers, focal adhesion kinase
(FAK) and paxillin (PAX). PEI-MSC showed accelerated integrin signalling and focal adhesion points clustering differed over time between treated and untreated MSC. The focal
adhesion points (arrows) of PEI-MSC appeared more evenly distributed and less accentuated. Scale bars: 20 mm. Microphotographs represent two technical replicates of pooled
hBM-MSC (3 donors) per group out of a single experiment.
(b) Quartz Crystal Microbalance with Dissipation (QCM-D) experiments to evaluate seeding and spreading capacities of MSC upon PEI/NP treatment in real time. QCM-D meas-
ures surface adsorption by means of shifts in the resonance frequency (Df) and damping behaviour (bandwidth, DG) of an AT-cut quartz crystal. While a negative frequency shift is
related to the amount of adsorbed mass, damping is the result of dissipative energy losses induced by the adsorbed mass. The relation between frequency and bandwidth represents
the mass-sensor coupling, and a loosely coupled mass dissipates more energy (larger DG) than a firmly coupled mass (smaller DG). The figure displays representative graphs of
three separate measurements for each condition. QCM-D data correlate with the microscopic images (crystal violet staining) taken after the mass sensitive measurements. Seeding
density: 40,000 cells per sensor. Viable MSC can be distinguished from dead cells (negative control; 10 min. 57 °C; red graphs, right microphotograph in lower row) showing
absence of significant frequency and bandwidth shifts; scale bar: 200 mm. Untreated viable MSC (black graphs) adhered within 30 minu with subsequent typical spreading signal
(gradual decrease in bandwidth) in the following 4 hours. In contrast, PEI-MSC (yellow graphs) displayed slower adhesion and almost no spreading (stable bandwidth), indicating
weaker adhesion. PEI-NP-MSC (blue graphs) also displayed slow adhesion, but typical spreading, although delayed and less pronounced than in MSC.
(c) Adhesion capacity of MSC and PEI/NP treated MSC under dynamic shear stress conditions to endothelial cells that were activated by TNFa. Flow chamber adhesion data of
untreated and PEI/NP treated MSC were compared with ANOVA followed by Tukey's multiple comparisons test (*p < 0.05; ***p < 0.0001). Error bars: SD. Arrows indicate exemplary
adherent MSC; scale bar: 200mm. N = 8−14, each data point represents the mean of cell counts of 5−12 individual experiments per group.
(d) Adhesion capacity of MSC and PEI/NP treated MSC under dynamic shear stress conditions to endothelial cells with or without TNFa activation as well as to CHO cells lacking
intact adhesion molecules. Flow chamber adhesion data of untreated MSC with or without TNFa activation and to CHO cells were compared with ANOVA followed by Tukey's multi-
ple comparisons test (****p < 0.001); Flow chamber adhesion data of PEI/NP treated MSC with or without TNFa activation were compared with two-tailed t-test (****p < 0.0001).
Error bars: SD. N = 2 −12, each data point represents the mean of cell counts of 1 −8 individual experiments per group.
(e), (f) Adhesion capacity of MSC and PEI/NP treated MSC under dynamic shear stress conditions to endothelial cells with TNFa activation and blocking antibodies against CD44
or CXCR4. Flow chamber adhesion data of untreated and PEI/NP treated MSC with or without blocking antibodies were compared with two-tailed t-test (****p < 0.0001). Error bars:
SD. N = 3-14, each data point represents the mean of cell counts of 2 −9 individual experiments per group. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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Fig. 3. Human MSC migration in vitro and their adhesion and migration in the lung in vivo
(a) Migration capacity expressed by % of untreated MSC and PEI treated MSC with or without additional chemoattractants or human platelet lysate (HPL). Migration data of
untreated and PEI treated MSC were compared for each condition with two-tailed t-test (*p < 0.05), N = 3, each data point represents one biological replicate per group Error bars:
SD.
(b) Immunofluorescence and associated quantification of MSC accumulation in the lung after intravenous application of 5 £ 106 treated or untreated eGFP+ MSC in a rat model
of unilateral hippocampal quinolinic acid (QA)-induced brain injury. Animals were sacrificed 24 h after application. Untreated and treated MSC were detected in the lumina of the
small vessels (arrows), but also in close vicinity to the vessels (arrowheads). von Willebrand factor (vWF): red; GFP: green; DAPI: blue; scale bars: 100 mm. Intraparenchymal and
intravascular cell numbers were compared for untreated MSC, PEI treated MSC or PEI-NP treated MSC with two-tailed unpaired t-test (***p < 0.001). N = 3 per group. Intravascular
data represent 9 data points generated from 3 sections per mouse (n = 3). Intraparenchymal data represent 80 −180 data points generated from 6 to 9 micrographs from 8 to 30 sec-
tions. Error bars: SEM.
(c) Numbers of untreated MSC, PEI-MSC or PEI-NP-MSC detected in the vasculature and parenchyma. Cell numbers of untreated or PEI/NP treated MSC were compared for intra-
parenchymal or intravascular localisation with ANOVA followed by Tukey's multiple comparisons test (*p < 0.05, ***p < 0.001). N = 3 per group. Intravascular data represent 9 data
points generated from 3 slides from N = 3 mice; intraparenchymal data represent 180 data points obtained from 30 slides per mouse (6 micrographs per section). Error bars: SEM.
(d) Immunofluorescence of CCL2 and SDF-1 in the pulmonary vasculature and parenchyma of rats administered with untreated MSC, PEI-MSC or PEI-NP-MSC. CCL2: red; GFP:
green; DAPI: blue; scale bars: 100 mm SDF-1: red; GFP: green; DAPI: blue; scale bars: 50 mm (MSC, PEI-MSC), 100 mm (PEI-NP-MSC). (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. Targeted homing of human MSC in the brain and their therapeutic efficacy
(a) Targeted homing of untreated MSC, PEI-MSC or PEI-NP-MSC assessed in different regions of the brain after intravenous application of 5 £ 106 treated or untreated eGFP+
MSC to a rat model of unilateral hippocampal QA-induced brain injury. Treated or untreated MSC were applied 7 days after QA injury, and animals were sacrificed 24 h after applica-
tion. Cell numbers of untreated or PEI/NP treated MSC were compared between lesioned and non-lesioned tissue as well as within lesioned and non-lesioned tissue in the different
brain regions with ANOVA followed by Tukey's multiple comparisons test (*p < 0.05, **p < 0.01, ***p < 0.001). N = 3 per group. The columns represent 80−160 data points generated
from 8 to 9 micrographs from 8 to 21 sections. Error bars: SEM.
(b) Quantification of untreated MSC, PEI-MSC or PEI-NP-MSC assessed in the parenchyma of the lesioned brain hemisphere (unilateral hippocampal QA-induced excitotoxic
brain injury model), and the parenchyma of the non-lesioned lung. Intraparenchymal cell numbers in the lung and the different lesioned brain regions were compared for untreated
or PEI/NP treated MSC with two-tailed t-test (*p < 0.05; ***p < 0.001). N = 3 per group. The columns represent 80−180 data points generated from 6 to 9 micrographs from 8 to 30
sections. Error bars: SEM.
(c) Brain/lung ratio of untreated MSC, PEI-MSC or PEI-NP-MSC for hippocampus and cortex in the unilateral hippocampal QA-induced excitotoxic brain injury model.
(d) Analysis of motor coordination using the rotarod, the tight rope and the corner turn test in mice exposed to 45 min. of transient focal cerebral ischemia followed by intrave-
nous transplantation of either eGFP+ MSC or eGFP+ PEI-MSC during reperfusion. A total of 1 £ 106 cells were grafted per experimental condition. Controls received PBS only, N = 7
animals per group. Impairment of motor coordination was assessed on days 10, 20 and 28. Functional performance data of the groups received either PBS, untreated MSC, or PEI-
MSC were compared with ANOVA followed by Tukey's multiple comparisons test (*significantly different from controls, p < 0.05; #significantly different from mice treated with
MSC, p < 0.05) .
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face of untreated MSC and PEI-MSC (Supplementary Fig. 1). In con-
trast, the CXCR4 signal was strongly increased on the surface of PEI-
NP-MSC where it appeared in condensed patterns that co-localized
with the PEI-NP complexes, indicating a mechanistic impact of NP
deposits on CXCR4 protein expression (Fig. 1a; Supplementary Fig.
1). PEI treatment alone resulted in decreased expression of total
CXCR4 protein (intracellular and on the MSC surface), but combinedtreatment of MSC did not affect either CXCR4 mRNA or CXCR4 total
protein expression, suggesting a post-translational regulation of
CXCR4 on the surface of PEI-NP-MSC (Fig. 1b,c; Supplementary Fig.
1b). MSC treatment with either PEI or PEI-NP resulted in increased
expression of CD44 total protein, whereas only PEI treatment
increased CD44mRNA levels (Fig. 1b,c). Soluble CD44 protein was not
detected in the supernatants of untreated or treated MSC, only insol-
uble CD44 in the MSC lysate. This indicates that the decreased
12 R. Sch€afer et al. / EBioMedicine 60 (2020) 102987detectability of CD44 molecules on the surface of PEI-MSC was medi-
ated by cationic interaction of PEI with membrane bound CD44 mole-
cules rather than by splitting off the soluble CD44 fraction
(Supplementary Table 1). Significant changes of CCR4, endoglin, and
VCAM-1 mRNA were also observed, confirming a transcriptional
effect of PEI treatment (Fig. 1c). PEI/NP treatment impacted the pro-
duction and secretion of trophic factors and EV release, but not the
expression of CD10, CD140b, GD2, or PDPN proteins on MSC, or MSC
viability, tri-lineage differentiation potential, or immunomodulatory
capacity (Supplementary Fig. 2,3).
Next, we investigated the functional impact of PEI/NP treatment
on MSC adhesion. Integrin signalling was accelerated in PEI-MSC,
which had weaker focal adhesion points (Fig. 2a). PEI treatment
caused adherent MSC to cover a smaller surface area than untreated
MSC, suggesting that PEI has a membrane condensation effect. In
contrast, PEI treatment did not affect the size of detached MSC (Sup-
plementary Fig. 2b, 4). In addition, PEI-MSC featured delayed adhe-
sion kinetics, and quartz crystal microbalance with dissipation
analysis revealed impaired seeding and spreading capacities of MSC
upon PEI treatment (Fig. 2b; Supplementary Fig. 4).
Under dynamic shear stress, modelling the physical stress to
which MSC are exposed after intravascular administration, PEI treat-
ment of MSC decreased their adhesion capacity to endothelial cells
(EC), whereas PEI-NP-MSC showed increased adhesion. This sug-
gested that PEI treatment not only reduced the detectability of MSC
adhesion receptors but also blocked their functions, and that the
higher expressed CXCR4 molecules on PEI-NP-MSC were functional
as well. Depletion of TNFa and antibody-mediated blocking of CD44
and CXCR4 reduced the adhesion of MSC and PEI-NP-MSC to EC, but
did not further reduce the already impaired adhesion capacity of PEI-
MSC (Fig. 2c−f). This confirmed the functional relevance of adhesion
molecules and the interactions with their ligands on EC for the modu-
lation of stem cell adhesion.
3.1. PEI treatment modifies MSC migration in vitro
Exiting the vasculature into the surrounding tissue is a crucial step
in stem cell homing. Therefore, we analysed the MSC transmigration
ability in vitro. PEI treatment increased MSC migration in the pres-
ence of PDGF, CCL2 or human platelet lysate (HPL) indicating the
involvement of multiple mechanisms beyond the CCL2-CCR4 axis in
PEI-MSC migration (Fig. 3a). To address MSC functional heterogene-
ity, we explored the susceptibility of distinct MSC subpopulations to
PEI treatment with respect to their migration capacities. PEI treat-
ment promoted migration of CCR4+ and CD140b+ subpopulations
but either did not promote or even reduced migration of CD10+ and
GD2+ subpopulations (Supplementary Fig. 5).
Functional blocking of cell adhesion receptors modulates MSC
adhesion to lung endothelium after systemic administration
We hypothesized that adhesion to the lung endothelium could
limit the effect of stem cell therapies, and, therefore investigated
whether PEI treatment could circumvent that. Hence, we intrave-
nously administered eGFP+ MSC, PEI-MSC and PEI-NP-MSC to a rat
model of unilateral hippocampal quinolinic acid (QA)-induced excito-
toxic injury. We found untreated MSC, PEI-MSC and PEI-NP-MSC in
the lumina of the small pulmonary vessels and in close vicinity to the
vessels, indicating transmigration towards the lung parenchyma
(Fig. 3b). In line with their reduced adhesion rate to EC in vitro, signif-
icantly fewer PEI-MSC were detected in the vessels and in the lung
parenchyma. In contrast, the number of PEI-NP-MSC in the vessels
was higher compared to untreated MSC or PEI-MSC (Fig. 3c). To
investigate the involvement of the molecules that were induced by
PEI/NP treatment in vitro we next analysed the ligands of CCR4, i.e.
CCL2, and CXCR4, i.e. SDF-1, in the lung as well as their possible inter-
actions with the transplanted MSC. Immunostaining of the pulmo-
nary vessel walls demonstrated that PEI-MSC showed less interactionwith CCL2 in the lung, likely due to their impaired adhesion capacity
(Fig. 3d). Our results indicate that PEI treatment of MSC reduces their
adhesion to endothelial cells and thereby their accumulation in blood
vessels in vivo, which could enhance their therapeutic efficacy.
Functional blocking of cell adhesion receptors and increasing
CCR4 expression results in MSC targeted homing and improves their
therapeutic efficacy after systemic administration
We next tested directly whether the decreased EC adhesion
indeed translated to improved delivery to the target area using the
unilateral QA brain injury rat model. This model was chosen because
of the known feature of QA to increase SDF-1 and CCL2 in astroglia
[38]. We found higher concentrations of the CCR4 ligand CCL2, and
the attractants MIP-1a and IP-10, indicating the presence of an
inflammatory milieu to attract systemically administered eGFP+ MSC
to the brain (Supplementary Figs. 6 and 7). We detected more trans-
planted MSC in the lesioned hemisphere confirming the known MSC
tropism towards tissue injury [4]. Due to their reduced first pass
accumulation in the lung we expected to find more PEI-MSC than
untreated MSC in the brain lesion. Indeed, within the lesioned brain
tissue, the number of PEI-MSC was strongly increased compared to
the number of untreated MSC and PEI-NP-MSC. No differences of the
homing patterns of treated or untreated MSC were observed in non-
lesioned brain areas (Fig. 4a). After i.v. application, PEI-MSC had
improved migration potential in the brain compared to the lung
(Fig. 4b,c).
We also analysed the effect of PEI treatment of MSC on recovery
using a ischemic stroke mouse model, whereby mice are exposed to
45 min. of transient focal cerebral ischemia followed by intravenous
transplantation of either eGFP+ MSC or eGFP+ PEI-MSC during reper-
fusion. Although both i.v. administered MSC and PEI-MSC improved
recovery of mice after stroke, PEI-MSC performed significantly better
than untreated MSC at acute and subacute disease stages (Fig. 4d).
Further, neuronal, glial and oligodendrocyte markers were detected
in close vicinity to PEI-MSC and untreated MSC, with a trend to
higher co-expression in PEI-MSC (Supplementary Fig. 8), indicating
that the targeted PEI-MSC were stimulating tissue repair.
In the QA injury model, MSC were found in close proximity to the
brain vasculature where, contrary to the lung, most MSC transmi-
grated from the vessel lumen towards the parenchyma (Supplemen-
tary Fig. 7a). In the lesioned brain in particular, PEI-MSC accumulated
in areas of high CCL2 protein expression, which is a pro-migratory
protein (Supplementary Fig. 7b). To understand the mechanism
underlying the increased MSC migration potential in the lesioned
brain compared to the lung, we analysed the levels of CCL2 and other
pro-migratory proteins. Unexpectedly, we detected much higher
concentrations of pro-migratory proteins in the lungs than in the
brains of QA injury and haemorrhagic stroke (SP-SHR) models as well
as in healthy rats (Supplementary Fig. 9). We also asked if the lung
and brain EC, as “gatekeepers” of MSC transmigration from the vascu-
lature into the tissue, might feature different contents of pro-migra-
tory factors. Indeed, more CCL2 and TGFb were detected in brain EC
than in lung EC (Supplementary Fig. 10). Thus, we conclude that lung
EC, expressing lower amounts of pro-migratory factors and effec-
tively separating the transplanted cells from the cytokines located
beneath the intact EC layer, play a relevant role in the decreased MSC
transmigration rate in the lung compared to the lesioned brain.
Altogether, we propose that suppression of PEI-MSC adhesion to
lung EC decreases accumulation of PEI-MSC in the lung and, together
with increased CCR4 expression, enables increased targeted homing
to the lesioned brain tissue.
3.2. PEI treatment modifies MSC migration in vivo
As MSC show tumour tropism [4], we finally assessed the MSC`s
trans-hemispheric migration rate towards previously implanted glio-
blastoma cells to validate their in vivo migration capacities. More
Fig. 5. In vivo intracerebral application of migration- and adhesion-modulated MSC in an orthotopic model of glioblastoma
(a) 1£ 105 ds-red-U87MG cells were injected into the brain of NMRI mice, and a T2-weighted MR-anatomy acquired 18 days post injection of ds-red-U87MG cells. 1 £ 105 eGFP
+ MSC or eGFP+ PEI-MSC were injected into the contralateral side on day 22 after intracerebral injection of the ds-red-U87MG cells. Tumours are indicated with arrows.
(b) Quantification of eGFP+ MSC and eGFP+ PEI-MSC in the tumor area 6 days after intracerebral injection of GFP-MSC (N = 4 per group). The columns represent 63 or 111 data
points obtained from 20 to 25 sections per mouse brain (3−4 micrographs analysed per section). Cell numbers of untreated MSC and PEI-MSC were compared with two-tailed t-test
(**p < 0.01); Error bars: SEM.
(c) eGFP+ MSC and eGFP+ PEI-MSC (green) highlighted with arrows in the ds-red-U87MG (red cells) tumour area 28 days after intracerebral injection of ds-red-U87MG and 6
days after injection of 1 £ 105 eGFP+ MSC or eGFP+PEI-MSC into the contralateral hemisphere. Scale bar: 100mm. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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observed increase of the in vitro MSC migration capacity by PEI treat-
ment. This provides further evidence for their superior in vivo migra-
tion capacities and confirms migration through tissue as a relevant
mechanism for stem cell therapiesefficacy (Fig. 5).
4. Discussion
The present study shed light on the factors influencing MSC hom-
ing to the brain from the mechanistic perspective of adhesion- and
transendothelial migration as key tools that can be modulated for
increased and sustained delivery efficacy of systemically adminis-
tered stem cells. Furthermore, our data strongly suggest that modu-
lating cell surface properties, as exemplified by PEI treatment, can
help not only to escape the stem cell entrapment in the lung vessels,
but also to promote their migration within the targeted organ evi-
denced by improved homing and therapeutic efficacy in in vivo mod-
els of brain injury.
Particularly MSC are being evaluated as a promising cell therapy
source for various clinical applications due to their powerful immu-
nomodulatory and regenerative potential [39].
Despite featuring chemokine-mediated tropism toward lesioned
or inflamed tissue, previous studies reported that only few of system-
ically applied MSC home to the target tissue with the majority of the
cells being “trapped” in parenchymal organs such as the lung [4,40].
The observation that a stem cell transplant can exert some thera-
peutic effects even when most of the cells do not reach the damaged
organ has led to the hypothesis that these cells systemically release
regenerative or immunomodulatory factors that may sufficiently
repair the local damage such as an infarcted heart or brain [11].
However, the sustainable implementation of stem cell therapies is
still hampered by their inconsistent efficacies, and it is reasonable to
assume that the loss of many of the transplanted cells to non-
lesioned organs or tissue is a relevant cause for this shortcoming.
Moreover, such first-passage filtering of stem cells from the circula-
tion to non-lesioned tissue can be dangerous for various organs, e.g.
leading to cerebral or pulmonary embolism [9,41]. Thus, directing
the transplanted cells to the target region could reduce side effects
and improve the therapeutic efficacy of the stem cell graft. We show
that targeting stem cell homing by modulating cell adhesion and che-
mokine receptors can enhance their therapeutic efficacy.
PEI-MSC showed lower detectability/expression of the integrin
subunit CD49a, endoglin, CD44 and VCAM-1, and decreased adhesion
to EC under dynamic shear stress conditions. Further, our observa-
tions using blocking antibodies indicate that CD44 and CXCR4 are not
substantially involved in PEI-MSC interactions with EC, and that PEIdecreases the adhesion of MSC on EC regardless of EC’s activation sta-
tus. A compensatory increase in CD44mRNA and CD44 protein on PEI
treatment indicates a potential feedback to CD44 molecules
impairment on the MSC surface. Moreover, PEI appears to disrupt the
interaction of CD44 molecules with their natural ligands on the EC
surface and with anti-CD44 antibodies, without inducing CD44 cleav-
age on MSC [42]. Cationic agents can interfere with signalling path-
ways such as suppression of TNFa-induced VCAM-1 expression [43].
Moreover, CD44 is involved in the expression of chemokines and
receptors such as CXCR5 [44]. The increased CCR4 expression in PEI-
MSC can be explained by intracellular PEI effects, including interac-
tions with negatively charged DNA and/or RNA, possibly also involv-
ing CD44, with the regulatory pathways of CCR4 that remain to be
further elucidated.
Pro-inflammatory cytokines are potent attractors for MSC [5,20],
and they can migrate toward the lesioned striatum in the 6-hydroxy-
dopamin PD model [45]. Similarly, in the QA lesion model we
detected higher concentrations of pro-inflammatory chemokines in
the lesioned hemisphere. As CCR4 expression was increased on PEI-
MSC we hypothesized that its ligand CCL2 plays a substantial role in
their increased homing capacity. We confirmed the increased expres-
sion of CCL2 in the lesion, hereby identifying the CCR4-CCL2 axis,
additionally to the previously described CCR2-CCL2 axis [46], as a
contributor to stem cell homing. Previously, it was reported that
integrins are involved in the entrapment of MSC in the lung [6]. Our
data confirm that MSC accumulation in the lung is not merely the
result of MSC congesting small pulmonary vessels but also depends
on the function of their adhesion receptors.
We conclude that the targeted homing of PEI-MSC to the site of
injury after systemic application was enhanced by their lower adhe-
sion capacity to inactivated EC without compromised chemokine
receptors but increased CCR4 expression. The observed condensation
effects of PEI treatment on the MSC membrane may have further
facilitated their passage through the small vessels of the lung.
We excluded non-specific MSC adhesion to EC by iron NP com-
plexes as treated or untreated MSC did not attach to CHO-A5 cells,
yet mechanical force can increase CXCR4 expression on stem cell sur-
faces [13]. Thus, NP complexes, acting as mechanical stimuli, are
likely to trigger “in-side-out flipping” of CXCR4 molecules thereby
increasing MSC adhesion capacity. The increased adhesion potential
of PEI-NP-MSC might be suitable for local stem cell applications pre-
venting the undesired migration of the stem cell graft through the
vasculature toward non-lesioned regions.
PEI-MSC featured increased secretion and/or production of tro-
phic factors suggesting the possible optimization of MSC therapeutic
effects. Indeed, we observed a significant improvement early after
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of the observation period the in vivo effects of both groups con-
verged, performing equally better than vehicle controls. At this time
the numbers of PEI-MSC and untreated MSC were not significantly
different in the post mortem analyses, likely due to secondary stem
cell loss in the ischemic extracellular milieu [33], highlighting the rel-
evance of (stem) cells` homing for their therapeutic efficacy.
Blocking CXCR4 or CD44 on PEI-NP-MSC did not reduce their
adhesion rates below controls, and it is likely that the PEI+/-NP effects
are not restricted to the receptors and factors we analysed but might
also apply to a greater variety of molecules located on the cell surface
and in the cytoplasm of transplanted MSC, as well as in the host vas-
culature and tissue. In order to identify possible effects of PEI on other
extracellular and cytoplasmic molecules, a broad proteomic screen-
ing including integrins, PECAM-1, ICAM-1, E-/L-selectin, and glyco-
proteins should be considered for future studies. Also, other cationic
agents such as cationic click polymers, lipids, polysaccharides, or salts
may be worthy candidates for thorough evaluation of their impact on
stem cell homing.
We modulated the adhesion and migration capacities of MSC and
found that this increased their targeted homing rates by reducing the
first-passage filtering in the lung, and, notably, improved their thera-
peutic efficacy. Moreover, beyond its adhesion-modulating role, PEI
treatment enhanced the tumour tropism of intracerebrally injected
MSC hereby confirming its impact on stem cell in vivo migration
potential. This finding is of particular interest for implementation of
MSC as delivery vehicles for oncolytic adenoviral therapy, particularly
acknowledging the high variability of MSC’s tumour tropism across
different glioma models and delivery routes [4].
We validated our findings in vitro as well as in vivo in preclinical
small animal models including stroke. Yet, rodent models assessing
vascular cognitive impairment may be limited due to differences to
larger animals or human, such as paucity of white matter [47], sug-
gesting further validation in larger species is necessary. Moreover, a
clinical monitoring of the stem cell grafts distribution, e.g. applying
non-invasive imaging technologies, would be valuable to track the
fate of the graft in the patient. This may not only allow to assess an
individual efficacy profile, but also help to reduce, or even prevent,
side effects. Specifically, iron or gadolinium-(NP) labelled stem cells
can be detected by MRI [48,49], or, more recently, advanced
approaches were developed using reporter gene imaging that could
combine graft tracking with its functional assessment such as viabil-
ity or therapeutic capacities [50].
The concept described here elucidates the interactions of stem cell
transplants with lesioned and non-lesioned host tissue, specifically
pulmonary endothelium and brain tissue. Hereby, we identified the
adhesion of transplanted stem cells to endothelium and their migra-
tion capacity as relevant MoAs for their therapeutic efficacy. This
paves the way towards future production of customized cellular
grafts for respective clinical indications in regenerative medicine and
oncology, thereby contributing to realizing the full potential of
(stem) cell therapies.
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